Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.

Frontiers in immunology - 1 Jan 2021

Pan Yi-Hui, Zhang Jia-Xing, Chen Xu, Liu Fei, Cao Jia-Zheng, Chen Yu, Chen Wei, Luo Jun-Hang

Abstract excerpt

Background: Only a proportion of patients with bladder cancer may benefit from durable response to immune checkpoint inhibitor (ICI) therapy. More precise indicators of response to immunotherapy are warranted. Our study aimed to construct a more precise classifier for predicting the benefit of immune checkpoint inhibitor therapy. Methods: This multi-cohort study examined the top 20 frequently mutated genes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Immune Checkpoint Inhibitors

Share to Predictive Value of Tests

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34421886
DOI: 10.3389/fimmu.2021.643282
PMCID: PMC8371040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.PMID 34421886Read ↗

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune MicroenvironmentSemantic proximity Read ↗

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.Semantic proximity Read ↗

A TP53-based immune prognostic model for muscle-invasive bladder cancer.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

Identification of RB1 Gene as a Immune-Related Prognostic Signature Based on Tumor Mutation Burdens in Bladder CancerSemantic proximity Read ↗

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Risk stratification based on immune signature and prediction of immune checkpoint inhibitor’s efficacy for bladder urothelial carcinomaSemantic proximity Read ↗

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.